Parecoxib, valdecoxib, and cardiovascular risk.
Furberg
Curt D
CD
Psaty
Bruce M
BM
FitzGerald
Garret A
GA
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects*; D008565:Membrane Proteins; D015201:Meta-Analysis as Topic; D011355:Prodrugs / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D011451:Prostaglandin-Endoperoxide Synthases; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D013449:Sulfonamides / Q000009:adverse effects*; D000096926:Benzenesulfonamides
D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D008565:Membrane Proteins; D011355:Prodrugs; D011451:Prostaglandin-Endoperoxide Synthases; D013449:Sulfonamides; C406224:valdecoxib; D000096926:Benzenesulfonamides; C409945:parecoxib; C496540:PTGS2 protein, human